Can You Lose Weight Taking Ozempic? Clinical Evidence

Last reviewed: May 25, 2026

Last updated: May 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, clinical evidence demonstrates that GLP-1 receptor agonists like semaglutide can support weight loss in many individuals. The STEP clinical trials showed participants lost an average of 15-22% of baseline body weight over 68 weeks, significantly more than placebo.

However, outcomes vary widely among individuals due to genetic differences, metabolic factors, and lifestyle variables. Understanding your unique peptide genetic profile can help you and your provider evaluate whether this treatment approach aligns with your physiology and health goals.

How GLP-1 Medications Support Weight Loss Mechanisms

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. They signal satiety to your brain, reduce hunger hormone levels, and slow gastric emptying—the process by which food moves through your digestive system.

These combined effects typically result in reduced caloric intake without requiring conscious restriction. The medication addresses the neurobiological drivers of appetite rather than relying solely on willpower or dietary discipline.

Clinical Trial Data: Weight Loss Outcomes and Response Variability

Multiple randomized controlled trials have evaluated semaglutide efficacy. The STEP program enrolled over 4,500 participants across five trials, providing robust data on weight loss trajectories, side effect profiles, and factors associated with better or lesser response.

Trial Population / Finding	Weight Loss Range	Clinical Significance
STEP 1 (full program participation)	15-22% body weight	Superior to diet/exercise alone
STEP 2 (with T2DM diagnosis)	9-17% body weight	Additional glycemic benefit
STEP 3 (intensive behavioral intervention)	16-18% body weight	Combined approach value
Non-responders (15-20% of participants)	<5% body weight	Genetic/metabolic factors influence outcome

Genetic Variations That May Influence Individual Response

Your genetic makeup affects how your body responds to GLP-1 stimulation. Variants in the GLP1R gene (rs6923761), GIPR gene (rs1800437), and FTO gene (rs9939609) influence appetite regulation, satiety signaling, and metabolic capacity for weight loss.

Individuals carrying specific genetic variants may experience different appetite suppression intensity, metabolic rate changes, or gastrointestinal side effect profiles. These predispositions do not determine outcomes but may provide context for personalizing your treatment approach with your provider.

Who Benefits Most: Eligibility, Safety, and Provider Guidance

GLP-1 medications are most appropriate for individuals with BMI ≥27 with weight-related comorbidities or BMI ≥30, though your provider evaluates individual medical history, medications, and contraindications. History of pancreatitis, thyroid cancer, or multiple endocrine neoplasia type 2 typically contraindicates use.

A qualified healthcare provider should assess your baseline health status, current medications, and treatment goals before initiating therapy. They can also interpret genetic testing results in context of your specific clinical picture and help you monitor for gastrointestinal side effects during titration.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual peptide pathway variations—including GLP1R, GIPR, FTO, and MC4R gene variants—that relate to appetite regulation and metabolic response. These insights can support a more personalized conversation with your healthcare provider about whether GLP-1 treatment aligns with your genetic predispositions.

The genetic test reveals predispositions in peptide signaling pathways, not exact medication response. Carrying genetic variants associated with stronger or weaker GLP-1 receptor sensitivity may influence your likelihood of robust appetite suppression or the intensity of side effects, but many other factors—lifestyle, adherence, concurrent medications, and overall health—also determine outcomes.

Understanding your genetic context allows you and your provider to set realistic expectations, choose appropriate dosing strategies, and plan monitoring protocols tailored to your physiology. This precision-wellness approach helps move beyond one-size-fits-all assumptions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the STEP program and how many people did it enroll?

The article describes STEP as a set of five randomized trials of semaglutide that together enrolled over 4,500 participants. It says the program produced data on weight loss trajectories, side effect profiles, and factors linked to better or lesser response. Reported outcomes differed by arm, including one arm enrolling people with type 2 diabetes and another adding intensive behavioral intervention.

Does this article admit that some people simply do not respond to semaglutide?

Yes. It identifies a non-responder group, described as roughly 15 to 20 percent of participants, who lost under 5 percent of body weight. The article attributes that spread to underlying metabolic differences rather than effort, and repeatedly frames outcomes as varying widely between individuals. Anyone whose progress stalls is directed to their provider rather than to a self-adjustment.

Why does this article say semaglutide reduces intake without conscious restriction?

Because it acts on the neurobiological drivers of appetite rather than on willpower. The article says semaglutide mimics glucagon-like peptide-1, signals satiety to the brain, reduces hunger hormone levels, and slows gastric emptying, and that these combined effects typically lower calorie intake without deliberate restriction. It presents that as the mechanism behind the trial results rather than a guarantee of them.

What BMI thresholds does this article use when describing who these medications suit?

It describes GLP-1 medications as most appropriate for adults with a BMI of 27 or above who have weight-related conditions, or a BMI of 30 or above. The article immediately qualifies that by noting a provider evaluates individual medical history, current medications, and contraindications. A history of pancreatitis, thyroid cancer, or multiple endocrine neoplasia type 2 is described as typically ruling the medication out.

What did adding intensive behavioral support contribute in the STEP trials?

The article lists the arm combining semaglutide with intensive behavioral intervention among the program's results and frames it as demonstrating the value of a combined approach. It contrasts that with the arm enrolling participants who also had type 2 diabetes, where reported weight loss was lower but carried additional glycemic benefit. The main trial result is presented as superior to diet and exercise alone.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Ozempic For Losing Weight

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.